Literature DB >> 9709400

Molecular mechanisms of the reversal of imipramine-induced sodium channel blockade by alkalinization in human cardiac myocytes.

E Bou-Abboud1, S Nattel.   

Abstract

BACKGROUND: Alkalinizing agents reverse cardiotoxicity of a variety of sodium channel blockers, including tricyclic antidepressants, but their mechanisms of action are poorly understood.
PURPOSE: To establish the mechanisms by which alkalinization diminishes the sodium channel blocking action of imipramine.
METHODS: The whole-cell voltage-clamp technique was used to measure INa during a variety of depolarizing pulse protocols in isolated human atrial myocytes, in the presence and absence of imipramine. A three-state model was used to analyze state-dependent INa block.
RESULTS: Imipramine (1 and 5 microM) strongly inhibited INa. Experimental data and piecewise exponential analysis suggested significant binding to both activated and inactivated states. Alkalosis antagonized imipramine-induced INa blockade by increasing the unbinding rate, with intracellular alkalosis being more effective than extracellular alkalosis. The dissociation constant (Kd) for the inactivated state was increased from 0.55 to 1.40 microM by extracellular alkalosis and to 2.51 microM by intracellular alkalosis. Along with the reversal of drug-induced shifts in the inactivation curve, these data indicate that alkalosis on either side of the membrane antagonized drug interactions with the inactivated state. On the other hand, only intracellular alkalosis antagonized activated state block, increasing the Kd from 0.67 microM to 2.18 microM, while extracellular alkalosis left the activated state Kd unaltered at 0.67 microM.
CONCLUSIONS: Alkalinization antagonizes the INa-blocking action of imipramine by promoting unbinding from the receptor. Intracellular alkalosis has a particularly important effect related to the activated-state interaction. The lipid-soluble, uncharged moiety appears to be a critical determinant of imipramine's ability to dissociate from the Na+ channel receptor.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9709400     DOI: 10.1016/s0008-6363(98)00011-x

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  8 in total

1.  Pharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugs.

Authors:  Dan M Roden
Journal:  Card Electrophysiol Clin       Date:  2014-12-01

Review 2.  Pharmacological management of neuropathic pain.

Authors:  Gary McCleane
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 3.  Receptor function reserve: a new parameter for disease detection.

Authors:  H William Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12       Impact factor: 9.236

Review 4.  Antidepressants as analgesics.

Authors:  Gary McCleane
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 5.  A Literature Review of the Use of Sodium Bicarbonate for the Treatment of QRS Widening.

Authors:  Rebecca E Bruccoleri; Michele M Burns
Journal:  J Med Toxicol       Date:  2016-03

Review 6.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 7.  Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

8.  Mkk4 is a negative regulator of the transforming growth factor beta 1 signaling associated with atrial remodeling and arrhythmogenesis with age.

Authors:  Laura Davies; Jiawei Jin; Weijin Shen; Hoyee Tsui; Ying Shi; Yanwen Wang; Yanmin Zhang; Guoliang Hao; Jingjing Wu; Si Chen; James A Fraser; Nianguo Dong; Vincent Christoffels; Ursula Ravens; Christopher L-H Huang; Henggui Zhang; Elizabeth J Cartwright; Xin Wang; Ming Lei
Journal:  J Am Heart Assoc       Date:  2014-04-10       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.